NCT06584656

Brief Summary

Dementia is one of the leading causes of disability worldwide. Underlying biological mechanisms are crucial in preclinical stages of Alzheimer's disease (AD). Alterations in cerebral blood flow (CBF) and their relationship with AD blood-based biomarkers may be fundamental at early stages of the pathology. Physical exercise is a trigger to modify these biological mechanisms. Therefore, flADex aims to examine the acute effects of different types of exercise (resistance vs. aerobic vs. control) on CBF, AD blood-based biomarkers, and its cognitive implications in older adults. The hypothesis is that acute resistance or aerobic exercise will fluctuate levels of blood-based biomarkers, and will exert acute CBF changes combined with cognitive implications.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 6, 2024

Completed
1 month until next milestone

First Posted

Study publicly available on registry

September 5, 2024

Completed
20 days until next milestone

Study Start

First participant enrolled

September 25, 2024

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 2, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 2, 2025

Completed
Last Updated

March 25, 2025

Status Verified

March 1, 2025

Enrollment Period

3 months

First QC Date

August 6, 2024

Last Update Submit

March 24, 2025

Conditions

Keywords

Alzheimer's DiseaseExerciseCerebral Blood FlowBiomarkersAgingMagnetic resonance imaging

Outcome Measures

Primary Outcomes (1)

  • Change in Cerebral Blood Flow (CBF)

    Specific acquisition parameters for Pseudo continuous Arterial Spin Labeling (pCASL) sequence are used to determinate global and regional CBF in resting condition. Structural T1 sequence (only pre-condition) is used to coregisted the pCASL and delineate regions of interest for CBF. Time-of-flight angiography (TOF) (before pCASL pre-condition and before first pCASL post-condition) sequence is used to identify the carotid arteries. The unit of measurement of the CBF is expressed as milliliters per 100 grams of brain tissue per minute (mL/100 g/min).

    30 minutes before the experimental condition; and 20 minutes, 27 minutes and 34 minutes minutes after the experimental condition

Secondary Outcomes (8)

  • Change in Alzheimer disease blood-based biomarkers (Aβ42/40 ratio)

    5 minutes before the experimental condition; and 0 minutes, 50 minutes and 70 minutes after the experimental condition

  • Change in Alzheimer disease blood-based biomarkers (p-tau217, p-tau181, NfL and GFAP)

    5 minutes before the experimental condition; and 0 minutes, 50 minutes and 70 minutes after the experimental condition

  • Change in growth factors (BDNF)

    5 minutes before the experimental condition; and 0 minutes, 50 minutes and 70 minutes after the experimental condition

  • Change in growth factors (IGF-1)

    5 minutes before the experimental condition; and 0 minutes, 50 minutes and 70 minutes after the experimental condition

  • Change in episodic memory

    15 minutes before the experimental condition; and 60 minutes after the experimental condition

  • +3 more secondary outcomes

Other Outcomes (4)

  • Enjoyment

    5 minutes after the experimental condition

  • Physical engagement (in aerobic condition and resistance condition)

    During the experimental condition at minute 12, minute 20, and minute 30

  • Repetitions in reserve (in resistance condition)

    During the resistance condition after each exercise at minutes 5, 6, 7, 8, 9, 10, 11, 12 / 14, 15, 16, 17, 18, 19, 20, 21 / 23, 24, 25, 26, 27, 28, 29, 30

  • +1 more other outcomes

Study Arms (3)

Aerobic exercise group

EXPERIMENTAL

-Aerobic group. 30 min at 60-70% of the Maximal Heart Rate, moderate intensity on cycle.

Behavioral: Aerobic exercise condition

Resistance exercise group

EXPERIMENTAL

30 min at 4-6 RPE (OMNI-Resistance Exercise Scale of Perceived Exertion), 3 sets of 8 exercise/set, 40 sec/exercise. Moderate intensity using elastic bands and body weight.

Behavioral: Resistance exercise condition

Control

NO INTERVENTION

30 min seated watching a neutral documentary without cognitive engagement

Interventions

Aerobic session will last 30 min. The average intensity of the aerobic sessions will be 60-70% of the Maximal Heart Rate. Therefore, participant will perform a continuous moderate intensity aerobic bout of exercise on a cycle ergometer.

Aerobic exercise group

Resistance exercise will last 30 min at 4-6 RPE (OMNI-Resistance Exercise Scale of Perceived Exertion from 0-10). The bout of resistance exercise will include a combination of upper and lower body exercises using elastic bands and the participants' body weight as the primary resistance. Eight different exercises will be performed per set, with 40 seconds per exercise, for a total of 3 sets. The exercises are based on basic movement patterns and include: glute bridge, front plank, standing face pull, incline push-up, squat, pallof press, walking lunge and seated shoulder press.

Resistance exercise group

Eligibility Criteria

Age68 Years - 83 Years
Sexall
Healthy VolunteersYes
Age GroupsOlder Adult (65+)

You may qualify if:

  • Older adults
  • Aged 68-83 years
  • Non-pathological cerebral beta-amyloid status (based on Centiloid cut-point \<12 measured by PET-CT)
  • APOEe4 negative status
  • Willingness to participate in exercise interventions

You may not qualify if:

  • Pathological diagnosis related to physical or mental condition
  • No living in community settings during the study
  • MRI incompatibility
  • Ambulatory with pain or regular use of an assisted walking device
  • Severe cardiovascular or respiratory conditions
  • Participation in another clinical trial within the last 30 days

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

University of Granada

Granada, Andalusia, 18016, Spain

Location

Mind, Brain, and Behaviour Research Centre (CIMCYC, Centro de Investigación Mente, Cerebro y Comportamiento)

Granada, 18011, Spain

Location

Related Links

MeSH Terms

Conditions

Alzheimer DiseaseMotor Activity

Condition Hierarchy (Ancestors)

DementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersBehavior

Study Officials

  • Irene Esteban-Cornejo, PhD

    Department of Physical Education and Sports, Faculty of Sport Sciences, University of Granada, Spain.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ramon y Cajal Assistant Professor, PhD

Study Record Dates

First Submitted

August 6, 2024

First Posted

September 5, 2024

Study Start

September 25, 2024

Primary Completion

January 2, 2025

Study Completion

January 2, 2025

Last Updated

March 25, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will share

The protocol, statistical analyses plan and data management plan will be sharing open access. Data files including IPD, and corresponding data dictionaries, will be shared under restricted access and upon reasonable request (contact Irene Esteban-Cornejo) due to privacy issue and GDPR regulations. In principle, all collected IPD will be available for sharing under the \&#34;as open as possible, as closed as necessary\&#34; principle. The shared data files will be pseudonymized, only include participants who provided informed consent for sharing, and sharing is only possible when the data is used for research purposes regarding exercise, and brain health. This is stated at the informed consent files that the participants signed when they agree to participate.

Shared Documents
STUDY PROTOCOL, SAP, ANALYTIC CODE
Time Frame
The IPD data will be available 12 months after the primary outcome paper published. The data will be available 15 years after data collection.
Access Criteria
The specific process of data access will be determined in a later stage, but in general the research team supports data sharing. Roughly, data will be available upon reasonable request to the PI (Irene Esteban-Cornejo). The data requests must contain the purpose and aim of the research, but also specification of the data requested, and data analysis before data sharing. Data will only be shared for research purposes on exercise and brain health. In addition, we will follow \&#34;as open as possible, as closed as necessary\&#34; principle, so depending on this principle we will decide whether the data could be shared. A data access committee will be installed to approve data requests.
More information

Locations